Sugi Predict

Sugi Predict / Compounds / SCHEMBL994307

SCHEMBL994307

SCHEMBL994307

CC(=O)N1CCC2(CC1)CNC2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 4/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ CYP2C19 P33261 3/20 0.46
▸ MAPK1 P28482 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP2C9 P11712 4/20 0.45
▸ TSHR P16473 2/20 0.45
▸ CYP2D6 P10635 4/20 0.44
▸ CYP3A4 P08684 3/20 0.44
▸ CYP1A2 P05177 4/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HSD17B10 Q99714 5/20 0.42
▸ HPGD P15428 3/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ HIF1A Q16665 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29172907 0.98 USP2 (0.46) USP2ALDH1A1CYP2C19MAPK1MEN1
SCHEMBL20669201 0.88 ALDH1A1 (0.44) USP2ALDH1A1CYP2C19MAPK1MEN1
SCHEMBL13780351 0.86 CYP1A2 (0.47) USP2ALDH1A1CYP2C19MAPK1MEN1
Hydrochloric Acid SCHEMBL4263453 0.84 CYP1A2 (0.46) USP2ALDH1A1CYP2C19MAPK1MEN1
SCHEMBL26783934 0.84 USP2 (0.60) USP2ALDH1A1CYP2C19MAPK1MEN1
SCHEMBL16600524 0.82 CA2 (0.41) ALDH1A1CYP2D6CYP1A2HSD17B10
SCHEMBL15544126 0.81 USP2 (0.58) USP2ALDH1A1CYP2C19MAPK1MEN1
SCHEMBL12356595 0.81 CYP1A2 (0.59) USP2ALDH1A1MEN1KMT2ACYP2C9
SCHEMBL2112344 0.80 NAMPT (0.38) USP2ALDH1A1CYP2C19MAPK1TSHR
Hydrochloric Acid SCHEMBL744621 0.79 CYP1A2 (0.57) USP2ALDH1A1MEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 — — US disclosed
WO-2025215110-A1 NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS LES LABORATOIRES SERVIER (FR) 2025-10-16 — — WO disclosed
WO-2025021182-A1 CYP11A1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-01-30 — — WO disclosed
CN-119101069-A Spiro compounds and uses thereof 轩竹生物科技股份有限公司 2024-12-10 — — CN disclosed
WO-2024211834-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
EP-4313968-A2 SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2024-02-07 — — EP disclosed
WO-2023144736-A1 COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY ARTERIAL HYPERTENSION CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-03 — — WO disclosed
WO-2023144737-A1 COMPOSITIONS FOR PREVENTING OR TREATING HEART FAILURE (HF) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-03 — — WO disclosed
WO-2023098656-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE, LTD. (GB) 2023-06-08 — — WO disclosed
WO-2019015644-A1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF 四川海思科制药有限公司 2019-01-24 — — WO disclosed
US-8623857-B2 N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 MERCK SHARP & DOHME CORP. (US) 2014-01-07 — — US disclosed
EP-2205610-B1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS HOFFMANN LA ROCHE (CH) 2013-11-20 — — EP disclosed
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 MERCK SHARP & DOHME CORP. 2013-03-28 — — US disclosed
US-8293735-B2 Thienopyrimidine derivatives as P13K inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2012-10-23 — — US disclosed
US-8293735-B2 Thienopyrimidine derivatives as P13K inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2012-10-23 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN USP2 3191/4885ALDH1A1 824/4885CYP2C19 749/4885
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS PIK3CA, PIK3CD, PIK3CB USP2 3145/4885ALDH1A1 2075/4885CYP2C19 307/4885
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 PDPK1, PDK1, PDK3 USP2 2923/4885ALDH1A1 1910/4885CYP2C19 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.